{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:46:43Z","timestamp":1793692003086,"version":"4.5.1"},"reference-count":148,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.molmed.2021.10.005","type":"journal-article","created":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T16:11:35Z","timestamp":1637424695000},"page":"51-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Linking liver metabolic and vascular disease via bile acid signaling"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-4222","authenticated-orcid":false,"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2021.10.005_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0010","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0015","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0020","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","author":"Younossi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0025","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2008.01.075","article-title":"Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects","volume":"134","author":"Korenblat","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0030","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.atherosclerosis.2013.01.022","article-title":"Nonalcoholic fatty liver disease and serum lipoproteins: the multi-ethnic study of atherosclerosis","volume":"227","author":"DeFilippis","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.molmed.2021.10.005_bb0035","doi-asserted-by":"crossref","first-page":"15430","DOI":"10.1073\/pnas.0904944106","article-title":"Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity","volume":"106","author":"Fabbrini","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2021.10.005_bb0040","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2021.10.005_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","article-title":"Selective versus total insulin resistance: a pathogenic paradox","volume":"7","author":"Brown","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2021.10.005_bb0050","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2021.10.005_bb0055","doi-asserted-by":"crossref","first-page":"101094","DOI":"10.1016\/j.plipres.2021.101094","article-title":"Bile acids and their receptors in metabolic disorders","volume":"82","author":"Fiorucci","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0060","doi-asserted-by":"crossref","first-page":"41055","DOI":"10.1038\/srep41055","article-title":"Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis","volume":"7","author":"Cipriani","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2021.10.005_bb0065","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cmet.2020.10.026","article-title":"The power of plasticity \u2013 metabolic regulation of hepatic stellate cells","volume":"33","author":"Trivedi","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2021.10.005_bb0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0075","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0080","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jgh.14856","article-title":"Non-alcoholic fatty liver disease and the incidence of myocardial infarction: a cohort study","volume":"35","author":"Sinn","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0085","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0090","doi-asserted-by":"crossref","first-page":"l5367","DOI":"10.1136\/bmj.l5367","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.molmed.2021.10.005_bb0095","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis \u2013 from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molmed.2021.10.005_bb0100","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0105","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2021.10.005_bb0110","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the patatin-like phospholipase-3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0115","article-title":"Serial plasma phospholipid fatty acids in the de novo lipogenesis pathway and total mortality, cause-specific mortality, and cardiovascular diseases in the cardiovascular health study","volume":"8","author":"Lai","year":"2019","journal-title":"J. Am. Hear. Assoc."},{"key":"10.1016\/j.molmed.2021.10.005_bb0120","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of NLRP3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.molmed.2021.10.005_bb0125","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2021.10.005_bb0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/met.2019.0115","article-title":"High-risk atherosclerosis and metabolic phenotype: the roles of ectopic adiposity, atherogenic dyslipidemia, and inflammation","volume":"18","author":"Lechner","year":"2020","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.molmed.2021.10.005_bb0135","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","article-title":"Procoagulant imbalance in patients with non-alcoholic fatty liver disease","volume":"61","author":"Tripodi","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0140","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2016.06.001","article-title":"Preserved hemostatic status in patients with non-alcoholic fatty liver disease","volume":"65","author":"Potze","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0145","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1160\/TH16-09-0716","article-title":"Obesity\/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans","volume":"117","author":"Lallukka","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.molmed.2021.10.005_bb0150","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1161\/ATVBAHA.119.313215","article-title":"Direct amplification of tissue factor:factor V IIa procoagulant activity by bile acids drives intrahepatic coagulation","volume":"39","author":"Baker","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0155","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jhep.2016.09.022","article-title":"Bi-directional analysis between fatty liver and cardiovascular disease risk factors","volume":"66","author":"Ma","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0160","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/apt.16324","article-title":"Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease","volume":"53","author":"Park","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.molmed.2021.10.005_bb0165","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/ATVBAHA.114.305200","article-title":"Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study","volume":"35","author":"Long","year":"2015","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0170","doi-asserted-by":"crossref","first-page":"H21","DOI":"10.1152\/ajpheart.00577.2016","article-title":"Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators","volume":"312","author":"Fiorucci","year":"2017","journal-title":"Am. J. Physiol. Hear. Circ. Physiol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0175","doi-asserted-by":"crossref","first-page":"569914","DOI":"10.3389\/fphar.2020.569914","article-title":"L-arginine\u2013nitric oxide\u2013asymmetric dimethylarginine pathway and the coronary circulation: translation of basic science results to clinical practice","volume":"11","author":"Czir\u00e1ki","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0180","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/hh0102.102330","article-title":"Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview","volume":"90","author":"Ignarro","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0185","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1152\/physrev.00003.2018","article-title":"Homocysteine modification in protein structure\/function and human disease","volume":"99","author":"Jakubowski","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.molmed.2021.10.005_bb0190","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.22037","article-title":"The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats","volume":"47","author":"Distrutti","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2021.10.005_bb0200","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.molmed.2015.09.001","article-title":"Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders","volume":"21","author":"Fiorucci","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2021.10.005_bb0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cld.861","article-title":"Bile acid biology, pathophysiology, and therapeutics","volume":"15","author":"Chiang","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.molmed.2021.10.005_bb0210","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.metabol.2014.10.012","article-title":"Leptin in nonalcoholic fatty liver disease: a narrative review","volume":"64","author":"Polyzos","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.molmed.2021.10.005_bb0215","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.metabol.2010.09.003","article-title":"Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"60","author":"Polyzos","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.molmed.2021.10.005_bb0220","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.26946","article-title":"Reduced adiponectin signaling due to weight gain results in nonalcoholic steatohepatitis through impaired mitochondrial biogenesis","volume":"60","author":"Handa","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0225","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1210\/jc.2006-1067","article-title":"Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men","volume":"92","author":"Frystyk","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2021.10.005_bb0230","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/liv.14899","article-title":"Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease","volume":"41","author":"Lang","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.molmed.2021.10.005_bb0235","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c","volume":"113","author":"Watanabe","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2021.10.005_bb0240","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor","volume":"17","author":"Pineda Torra","year":"2003","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0245","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s42255-019-0074-3","article-title":"Metabolic messengers: fibroblast growth factor 15\/19","volume":"1","author":"Gadaleta","year":"2019","journal-title":"Nat. Metab."},{"key":"10.1016\/j.molmed.2021.10.005_bb0250","doi-asserted-by":"crossref","first-page":"25123","DOI":"10.1074\/jbc.M112.375907","article-title":"Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21","volume":"287","author":"Cyphert","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0255","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1210\/me.2015-1155","article-title":"Minireview: roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases","volume":"29","author":"Zhang","year":"2015","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0260","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast growth factor 21 \u2013 metabolic role in mice and men","volume":"38","author":"Staiger","year":"2017","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.molmed.2021.10.005_bb0265","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nrendo.2016.206","article-title":"FGF21 and metabolic disease in 2016: a new frontier in FGF21 biology","volume":"13","author":"Potthoff","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0270","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.semcdb.2015.09.021","article-title":"Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis","volume":"53","author":"Markan","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12967-016-0821-0","article-title":"Regulation of fibroblast growth factor 15\/19 and 21 on metabolism: in the fed or fasted state","volume":"14","author":"Guan","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.molmed.2021.10.005_bb0280","first-page":"193","article-title":"Fibroblast growth factor signaling in metabolic regulation","volume":"6","author":"Nies","year":"2015","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0285","first-page":"4750","article-title":"An engineered FGF21 variant, LY2405319, can prevent non-alcoholic steatohepatitis by enhancing hepatic mitochondrial function","volume":"8","author":"Lee","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0290","first-page":"1011","article-title":"Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatities in mice","volume":"6","author":"Liu","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0295","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0300","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","article-title":"Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis","volume":"102","author":"Sinal","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2021.10.005_bb0305","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI2961","article-title":"Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2","volume":"101","author":"Horton","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.molmed.2021.10.005_bb0310","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2174\/138955711796355258","article-title":"Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA","volume":"11","author":"Fiorucci","year":"2011","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0315","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic acid: an update of its pharmacological activities in liver disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0320","doi-asserted-by":"crossref","first-page":"173616","DOI":"10.1016\/j.ejphar.2020.173616","article-title":"Systematic review and meta-analysis of randomized controlled trials on the effects of obeticholic acid on the blood lipid profile: insights into liver disorders and liver cancer","volume":"889","author":"Guan","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0325","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.phrs.2018.07.014","article-title":"Future trends in the treatment of non-alcoholic steatohepatitis","volume":"134","author":"Fiorucci","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0330","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Fon Tacer","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0335","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1006\/cyto.1999.0485","article-title":"FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4","volume":"11","author":"Xie","year":"1999","journal-title":"Cytokine"},{"key":"10.1016\/j.molmed.2021.10.005_bb0340","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0345","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.molmed.2021.10.005_bb0350","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2021.10.005_bb0355","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.molmed.2021.10.005_bb0360","doi-asserted-by":"crossref","first-page":"G440","DOI":"10.1152\/ajpgi.00322.2009","article-title":"The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance","volume":"298","author":"Schreuder","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0365","first-page":"390","article-title":"Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome","volume":"41","author":"Barutcuoglu","year":"2011","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.molmed.2021.10.005_bb0370","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.clnu.2016.04.027","article-title":"FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss","volume":"36","author":"G\u00f3mez-Ambrosi","year":"2017","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.molmed.2021.10.005_bb0375","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0380","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1074\/jbc.M808818200","article-title":"Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis","volume":"284","author":"Bhatnagar","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0385","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1194\/jlr.M027094","article-title":"Dual actions of fibroblast growth factor 19 on lipid metabolism","volume":"54","author":"Wu","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0390","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.molmed.2021.10.005_bb0395","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/j.gastro.2007.06.019","article-title":"Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice","volume":"133","author":"van der Velde","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0400","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/164_2019_233","article-title":"Potential of intestine-selective FXR modulation for treatment of metabolic disease","volume":"256","author":"van Zutphen","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0405","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1053\/j.gastro.2016.12.037","article-title":"Intestinal farnesoid X receptor controls transintestinal cholesterol excretion in mice","volume":"152","author":"de Boer","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0410","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1053\/j.gastro.2018.11.061","article-title":"Small heterodimer partner and fibroblast growth factor 19 inhibit expression of NPC1L1 in mouse intestine and cholesterol absorption","volume":"156","author":"Kim","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0415","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1038\/ncomms10166","article-title":"Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction","volume":"6","author":"Jiang","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.molmed.2021.10.005_bb0420","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2337\/db16-0663","article-title":"An intestinal farnesoid X receptor\u2013ceramide signaling axis modulates hepatic gluconeogenesis in mice","volume":"66","author":"Xie","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.molmed.2021.10.005_bb0425","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.22627","article-title":"Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression","volume":"49","author":"Song","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0430","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cmet.2012.04.002","article-title":"A ceramide-centric view of insulin resistance","volume":"15","author":"Chavez","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.molmed.2021.10.005_bb0435","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1194\/jlr.M002782","article-title":"Glucose stimulates cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes","volume":"51","author":"Li","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0440","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.gastro.2016.08.057","article-title":"An intestinal microbiota\u2013farnesoid X receptor axis modulates metabolic disease","volume":"151","author":"Gonzalez","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0445","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance","volume":"21","author":"Fang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2021.10.005_bb0450","doi-asserted-by":"crossref","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","article-title":"Antiatherosclerotic effect of farnesoid X receptor","volume":"296","author":"Mencarelli","year":"2009","journal-title":"Am. J. Physiol. Hear. Circ. Physiol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0455","doi-asserted-by":"crossref","first-page":"G543","DOI":"10.1152\/ajpgi.90585.2008","article-title":"A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia","volume":"296","author":"Evans","year":"2009","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0460","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1194\/jlr.M500390-JLR200","article-title":"Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice","volume":"46","author":"Hanniman","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0465","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/ATVBAHA.109.197897","article-title":"A role of the bile salt receptor FXR in atherosclerosis","volume":"30","author":"Hageman","year":"2010","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0470","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.plipres.2009.11.001","article-title":"Bile acid-activated receptors in the treatment of dyslipidemia and related disorders","volume":"49","author":"Fiorucci","year":"2010","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0475","first-page":"579","article-title":"Counter-regulatory role of bile acid activated receptors in immunity and inflammation","volume":"10","author":"Fiorucci","year":"2010","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.molmed.2021.10.005_bb0480","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2174\/0929867324666170124151940","article-title":"Farnesoid-X receptor (FXR) as a promising pharmaceutical target in atherosclerosis","volume":"24","author":"Moris","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108270","article-title":"Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis","volume":"9","author":"Miyazaki-Anzai","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2021.10.005_bb0490","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.112.196519","article-title":"Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (\u2212\/\u2212) mice","volume":"343","author":"Hambruch","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2021.10.005_bb0495","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013238","article-title":"The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice","volume":"5","author":"Mencarelli","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2021.10.005_bb0500","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbalip.2006.09.018","article-title":"Effects of FXR in foam-cell formation and atherosclerosis development","volume":"1761","author":"Guo","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.molmed.2021.10.005_bb0505","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2021.10.005_bb0510","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1073\/pnas.0400046101","article-title":"Expression and activation of the farnesoid X receptor in the vasculature","volume":"101","author":"Bishop-Bailey","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2021.10.005_bb0515","doi-asserted-by":"crossref","first-page":"H114","DOI":"10.1152\/ajpheart.00087.2015","article-title":"Cystathionine \u03b3-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids","volume":"309","author":"Renga","year":"2015","journal-title":"Am. J. Physiol. - Hear. Circ. Physiol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0520","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1161\/CIRCULATIONAHA.107.704254","article-title":"Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport","volume":"116","author":"Tanigawa","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.molmed.2021.10.005_bb0525","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.3390\/ijms22137163","article-title":"Muricholic acids promote resistance to hypercholesterolemia in cholesterol-fed mice","volume":"22","author":"Gaillard","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2021.10.005_bb0530","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1194\/jlr.RA119000307","article-title":"Of mice and men: murine bile acids explain species differences in the regulation of bile acid and cholesterol metabolism","volume":"61","author":"Straniero","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.molmed.2021.10.005_bb0535","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2021.10.005_bb0540","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.21458","article-title":"The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells","volume":"45","author":"Keitel","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0545","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.3748\/wjg.14.5620","article-title":"Endocrine and paracrine role of bile acids","volume":"14","author":"Keitel","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0550","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbrc.2008.04.171","article-title":"Expression and function of the bile acid receptor TGR5 in Kupffer cells","volume":"372","author":"Keitel","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2021.10.005_bb0555","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/hep.23032","article-title":"The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders","volume":"50","author":"Keitel","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0560","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1074\/jbc.M209706200","article-title":"A G protein-coupled receptor responsive to bile acids","volume":"278","author":"Kawamata","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0565","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.molmed.2021.10.005_bb0570","doi-asserted-by":"crossref","first-page":"13689","DOI":"10.1038\/s41598-017-13102-y","article-title":"Gpbar1 agonism promotes a Pgc-1\u03b1-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2021.10.005_bb0575","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.01.139","article-title":"Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1","volume":"329","author":"Katsuma","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2021.10.005_bb0580","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/oby.2009.102","article-title":"Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism","volume":"17","author":"Patti","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.molmed.2021.10.005_bb0585","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1084\/jem.20171965","article-title":"Bile acids in glucose metabolism in health and disease","volume":"215","author":"Shapiro","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.molmed.2021.10.005_bb0590","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1677\/JOE-10-0009","article-title":"Gender-dependent effect of Gpbar1 genetic deletion on the metabolic profiles of diet-induced obese mice","volume":"205","author":"Vassileva","year":"2010","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0595","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbrc.2012.09.104","article-title":"Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic \u03b2 cells","volume":"427","author":"Kumar","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.molmed.2021.10.005_bb0600","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202001386R","article-title":"The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy","volume":"35","author":"Carino","year":"2021","journal-title":"FASEB J."},{"key":"10.1016\/j.molmed.2021.10.005_bb0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141082","article-title":"Reversal of endothelial dysfunction by gpbar1 agonism in portal hypertension involves a AKT\/FOXOA1 dependent regulation of H2S generation and endothelin-1","volume":"10","author":"Renga","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2021.10.005_bb0610","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1161\/ATVBAHA.113.301565","article-title":"Bile acid receptor TGR5 agonism induces NO production and reduces monocyte adhesion in vascular endothelial cells","volume":"33","author":"Kida","year":"2013","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0615","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.113.209288","article-title":"Stimulation of G protein-coupled bile acid receptor enhances vascular endothelial barrier function via activation of protein kinase A and Rac1","volume":"348","author":"Kida","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2021.10.005_bb0620","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1096\/fj.201801373RR","article-title":"Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis","volume":"33","author":"Carino","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.molmed.2021.10.005_bb0625","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2019_238","article-title":"The pharmacology of bile acids and their receptors","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0630","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.molmed.2021.10.005_bb0635","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0640","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/17460441.2021.1916465","article-title":"The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease","volume":"16","author":"Fiorucci","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.molmed.2021.10.005_bb0645","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0650","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2021.10.005_bb0655","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2021.10.005_bb0660","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.molmed.2021.10.005_bb0665","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a Phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0670","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.molmed.2021.10.005_bb0675","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.molmed.2021.10.005_bb0680","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1021\/acs.jmedchem.6b01873","article-title":"Topical intestinal aminoimidazole agonists of G-protein-coupled bile acid receptor 1 promote glucagon like peptide-1 secretion and improve glucose tolerance","volume":"60","author":"Lasalle","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0685","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.1021\/jm301071h","article-title":"Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists","volume":"55","author":"Duan","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0690","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1021\/jm500829b","article-title":"Discovery of intestinal targeted TGR5 agonists for the treatment of type 2 diabetes","volume":"58","author":"Duan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2014.05.031","article-title":"4-Benzofuranyloxynicotinamide derivatives are novel potent and orally available TGR5 agonists","volume":"82","author":"Zou","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0700","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cmdc.201200474","article-title":"2-Phenoxy-nicotinamides are potent agonists at the bile acid receptor GPBAR1 (TGR5)","volume":"8","author":"Martin","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.molmed.2021.10.005_bb0705","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/glia.21049","article-title":"The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain","volume":"58","author":"Keitel","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.molmed.2021.10.005_bb0710","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1021\/jm401873d","article-title":"Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors","volume":"57","author":"D\u2019Amore","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0715","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1021\/jm501273r","article-title":"Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands","volume":"57","author":"Festa","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.molmed.2021.10.005_bb0720","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/164_2019_230","article-title":"Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors","volume":"256","author":"Keitel","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0725","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2019_237","article-title":"Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists, and antagonists","volume":"256","author":"De Marino","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.molmed.2021.10.005_bb0730","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/dom.12636","article-title":"Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?","volume":"18","author":"Hodge","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.molmed.2021.10.005_bb0735","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpdd.34","article-title":"Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes","volume":"2","author":"Hodge","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.molmed.2021.10.005_bb0740","doi-asserted-by":"crossref","first-page":"42801","DOI":"10.1038\/srep42801","article-title":"BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis","volume":"7","author":"Carino","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149142100277X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149142100277X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:24:38Z","timestamp":1761463478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149142100277X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":148,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S147149142100277X"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2021.10.005","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linking liver metabolic and vascular disease via bile acid signaling","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2021.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}